Lorna Jane, an Australian activewear company, was recently fined AU$5 million after claiming that its new line of active clothing can stop the spread of COVID-19. The firm said that its clothing could eliminate the virus, thus preventing its spread.
According to BBC News, Lorna Jane released advertisements that say it is using a groundbreaking technology called LJ Shield for its clothing line. It was claimed that this could stop the "transfer of all pathogens."
What the court says on Lorna Jane’s claims
Based on the report, a judge said in a ruling that the company’s claim about LJ Shield is "exploitative, predatory and potentially dangerous." The legal action against Lorna Jane was filed by the Australian Competition & Consumer Commission (ACCC) after the firm started selling its clothing in July amid the COVID-19 pandemic.
The verdict was said to have been released by the federal court on Friday, July 23. The judge said that based on investigations, Lorna Jane has been telling the consumers it has a “reasonable scientific or technological basis" for its claims about its clothing with the LJ Shield.
However, the judge said there was actually no scientific basis for such a claim. For this false and misleading representation to the public, the court slapped the company with a hefty fine.
"This was dreadful conduct as it involved making serious claims regarding public health when there was no basis for them," chairman of the ACCC, Rod Sims, said. "The whole marketing campaign was based upon consumers' desire for greater protection against the global pandemic."
Lorna Jane accepts the judge’s decision
The company was said to have accepted the verdict but explained, it was also misled by its supplier. Lorna Jane claimed its supplier sold them a product that did not deliver what it claimed to be, and they are referring to what they called the LJ Shield technology that is supposed to be anti-viral and anti-bacterial.
Meanwhile, it was learned that this is not the first time that Lorna Jane was fined. As per The Guardian, just in July 2020, the company was fined $40,000 for its failure to seek proper approval for ads from the Therapeutic Goods Administration. As for this new issue, the company issued an apology for its customers while continuing to blame its supplier for the issue.


Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Australian Pension Funds Boost Currency Hedging as Aussie Dollar Strengthens
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



